newsfilter
← Latest News
GlobeNewswire·

ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference

  • ADARx Pharmaceuticals President & CEO Zhen Li, Ph.D. will attend a fireside chat at the UBS Global Biopharma Conference in London on Monday, November 16, 2026, at 2:00 p.m. GMT.
  • A live webcast of the event will be accessible via the investor website events page, with a replay archived for 90 days.
  • ADARx is a late-clinical stage biotechnology company developing next-generation siRNA therapeutics to treat various diseases.
  • The company's pipeline includes three clinical-stage hepatic-targeted programs: agazisiran, onvuzosiran, & ADX-626.
  • Two advanced preclinical extrahepatic-targeted programs in the pipeline are ADX-077 & ADX-199.
  • ADARx aims to expand its pipeline using proprietary technologies to control specific disease drivers with selective RNA-targeted therapies.
Company
ADARx Pharmaceuticals Inc.
Keywords
Nasdaq:ADRX, ADARx Pharmaceuticals Inc., ADARx, biotech, RNA, siRNA, siRNA therapeutics, UBS Global Biopharma Conf, ADRX